



Press Release

ABIONYX Pharma RACERS study in sepsis selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"

The late-breaking clinical results session will reveal exclusively RACERS' Phase 2a clinical data in sepsis that met primary and secondary endpoints

Two additional abstracts have been selected for presentation at the 2023 Kidney Week: an oral presentation on how CER-001 modulates ischemia/reperfusion injury in kidney grafts and a poster on the action of CER-001 in brain fog associated with acute kidney injury

Toulouse, FRANCE, Lakeland MI, USA, October 16, 2023, 7.00 a.m. CEST - ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant human apoA-1, announces that the Company's Phase 2b RACERS study in sepsis has been selected as a late-breaking clinical trial poster presentation at the 2023 American Society of Nephrology Annual Meeting taking place November 2-5, 2023 in Philadelphia, Pennsylvania.

Late breaking poster presentations are first-time international presentations of important results of randomized trials. These high-impact poster presentations provide the latest breakthroughs in clinical science and notable exposure and recognition for studies likely to have a significant impact on clinical practice and/or to make significant advances in a scientific field.

In total, three abstracts on CER-001, the world's only recombinant human apoA-1, including a late-breaking abstract have been accepted for poster and/or oral presentation at the 2023 American Society of Nephrology (ASN) "Kidney Week" Annual Meeting:

- A poster presenting clinical data from the RACERS Phase 2a trial of CER-001-for the treatment of sepsis, will be included in the late breaking clinical trial results session;
- An oral presentation on the ability of CER-001 to modulate ischemia reperfusion injury in kidney graft preservation systems; and
- A poster presenting preclinical data on CER-001 in brain fog associated with acute kidney injury.

Pr. Loreto Gesualdo, Head of the Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, Italy, and lead investigator of the RACERS study, stated: *“We are thrilled to share these results and believe that the selection of CER-001 data for a late-breaker presentation at ASN Kidney Week highlights the importance of new medical data about potential therapy options for sepsis treatment. RACERS generated robust data in patients, meeting the primary and secondary efficacy endpoints, while also demonstrating the safety of CER-001 as one of the most advanced biologic drugs. These data strongly support the decision to move CER-001 into a global pivotal trial for sepsis treatment. Additionally, the preclinical results on brain fog and reperfusion injury provide valuable data that support exploring potential additional indications for CER-001 in future clinical studies.”*

Cyrille Tupin, CEO of ABIONYX Pharma, added: *“Given the significant unmet medical need, we believe that CER-001’s potential in treating sepsis is real and important. We look forward to working with clinicians to further evaluate CER-001 in important long-term patient outcomes in sepsis. The acceptance of two other abstracts in brain fog and ischemia underscores the importance of our data and the efficacy of CER-001. We are actively engaged in strategic partnership discussions to progress CER-001 towards approval for sepsis and have expanded these interactions to include the potential for continued clinical development in Phase 3.”*

The schedule for ABIONYX presentations is as follows:

Session: Late-Breaking Clinical Trial Posters, 10:00 am EDT, November 2, 2023, Exhibit Hall

Poster Title: CER-001, an engineered High Density Lipoprotein, shows beneficial pleiotropic effects in patients with sepsis in the Phase 2a Randomized Control Trial RACERS

Poster #: TH-PO1158

Session: Oral Abstracts, 4:30 pm EDT, November 2, 2023, Room 115

Poster Title: CER-001, a recombinant HDL, modulates Ischemia/Reperfusion Injury (IRI) in hypothermic (HMP) and normothermic perfusion (NMP) solutions through pAKT/eNOS activation

Presentation #: TH-OR080

Session: Poster Session, 10:00 am EDT, November 3, 2023, Exhibit Hall

Poster Title: Tryptophan metabolism in AKI: a new target in kidney-brain axis

Poster #: FR-PO1818

All three posters will be available on the ASN website starting, Nov. 2, 2023 at 10.00 am EDT.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new apoA-I vectors used for targeted drug delivery.

Contacts:

NewCap

Investor relations
Nicolas Fossiez
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap

Media relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15